PPARG and Insulin resistance: Thiazolidinediones (TZD), such as rosiglitazone, represent a class of antidiabetic drugs that are capable of improving insulin resistance [69] through activation of the nuclear hormone receptor PPARγ [37], which serves also as a master regulator of late adipocyte maturation [34–36].